当前位置： SCI文献检索 > HEADACHE期刊下所有文献 > Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.

Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.

Abstract：

BACKGROUND:Eletriptan is a potent 5-HT(1B/1D) agonist with proven efficacy in the acute treatment of migraine in adults. OBJECTIVE:To evaluate the efficacy and tolerability of eletriptan 40 mg versus placebo in adolescent patients (aged 12-17). METHODS:A multicenter, double-blind, parallel-group, placebo-controlled trial was conducted comparing 40 mg of oral eletriptan with placebo for the treatment of migraine in adolescent patients. The primary efficacy endpoint was 2-hour headache response, and a number of secondary endpoints were also evaluated. An exploratory analysis evaluated which clinical and demographic characteristics might be correlated with high placebo response. RESULTS:Of 274 patients who treated a migraine attack, 267 were evaluated for efficacy (n = 138 eletriptan; n = 129 placebo) at 2 hours post-dose. There was no significant difference in 2-hour headache response for eletriptan 40 mg versus placebo (57% vs 57%), and no significant improvements were observed for any of the outcomes at 1 or 2 hours post-dose. By contrast, there was a significant advantage for eletriptan 40 mg in reducing headache recurrence within 24 hours post-dose (11% vs 25%, P= .028), and post hoc analyses showed statistically significant differences for sustained headache response rates (52% vs 39%; P= .04) and sustained pain-free response rates (22% vs 10%; P= .013). The strongest clinical predictor of placebo response was triptan-naïve status (i.e., no previous use of any triptan). Eletriptan 40 mg was well tolerated in this population, and the profile of adverse events was similar to that observed in Phase III trials in adult patients. CONCLUSIONS:The high placebo response rates reported here for 1- and 2-hour outcomes are in accordance with other studies of triptans in adolescent patients. The evaluation of treatment effect in adolescent migraine might benefit from use of more stringent outcome measures, such as headache recurrence, sustained headache response, and sustained pain-free response at 24 hours post-dose.

journal_name

Headache

journal_title

Headache

authors

Winner P,Linder SL,Lipton RB,Almas M,Parsons B,Pitman V

doi

10.1111/j.1526-4610.2007.00755.x

subject

Has Abstract

pub_date

2007-04-01 00:00:00

pages

511-8

issue

eissn

0017-8748

issn

1526-4610

pii

HED755

journal_volume

pub_type

杂志文章,多中心研究,随机对照试验

在线工具

Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.